Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous expanded CD34+ stem cells
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Parenteral
01
Overview
Autologous expanded CD34+ stem cells is an investigational cell therapy developed by Imperial College London for the treatment of chronic liver insufficiency and liver cirrhosis. The therapy involves mobilizing a patient's own hematopoietic CD34+ stem cells from the bone marrow into the bloodstream using granulocyte colony-stimulating factor (G-CSF). These cells are then collected via leukapheresis, expanded ex vivo, and re-infused into the patient via the hepatic artery or portal vein. The therapeutic rationale is based on the potential of CD34+ hematopoietic stem cells to differentiate into hepatocytes and other liver cell lineages, thereby regenerating damaged hepatic tissue and reducing fibrosis. A Phase I/II dose-escalation study (NCT00655707) has evaluated the safety, tolerability, and maximum tolerated dose of this approach in adults with chronic liver insufficiency or cirrhosis.
- Other names
- autologous expanded adult hematopoietic CD34+ stem cells
Beyond the preview
Go deeper on autologous expanded CD34+ stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous expanded CD34+ stem cells.